Death Cross Sparks Alarm: Social media erupted after UnitedHealth Group stock formed a death cross for the first time since early 2025, reminiscent of prior plunges. Traders pointed to regulatory headwinds like flat Medicare Advantage rates for 2027 as fueling the downside. The technical signal has amplified fears of further declines amid heightened volatility.
Buyers Circle Oversold Dip: Contrasting the bearish charts, some investors see value in the pullback to around $290, calling it an oversold opportunity near key supports. Discussions highlight cost-cutting via AI and potential earnings beats in April as catalysts for rebound. The company's revenue dominance in healthcare bolsters long-term conviction despite short-term noise.
Regulatory Pressures Mount: Ongoing DOJ scrutiny, congressional probes, and fallout from employee raise caps at 0-2% have raised red flags on social media. PR crises tied to recent leadership turmoil add to margin squeezes between claims and pricing. While divided, chatter suggests a battle between near-term risks and enduring market leadership.
Note: This discussion summary was generated from an AI condensation of post data.
UnitedHealth Group Insider Trading Activity
UnitedHealth Group insiders have traded $UNH stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $UNH stock by insiders over the last 6 months:
- CHARLES D. BAKER sold 27 shares for an estimated $9,613
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
UnitedHealth Group Revenue
UnitedHealth Group had revenues of $113.2B in Q4 2025. This is an increase of 12.31% from the same period in the prior year.
You can track UNH financials on Quiver Quantitative's UNH stock page.
UnitedHealth Group Congressional Stock Trading
Members of Congress have traded $UNH stock 15 times in the past 6 months. Of those trades, 6 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $UNH stock by members of Congress over the last 6 months:
- REPRESENTATIVE KEVIN HERN sold up to $500,000 on 12/23.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 3 purchases worth up to $80,000 on 12/19, 10/09, 09/05 and 1 sale worth up to $15,000 on 11/12.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
- REPRESENTATIVE RICHARD MCCORMICK has traded it 2 times. They made 1 purchase worth up to $15,000 on 11/05 and 1 sale worth up to $15,000 on 09/18.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 09/24.
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- SENATOR SHELDON WHITEHOUSE sold up to $50,000 on 09/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
UnitedHealth Group Hedge Fund Activity
We have seen 1,326 institutional investors add shares of UnitedHealth Group stock to their portfolio, and 1,981 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 20,260,160 shares (-73.6%) from their portfolio in Q4 2025, for an estimated $6,688,081,417
- CAPITAL RESEARCH GLOBAL INVESTORS removed 6,780,251 shares (-52.0%) from their portfolio in Q4 2025, for an estimated $2,238,228,657
- CARDANO RISK MANAGEMENT B.V. added 2,262,006 shares (+864.4%) to their portfolio in Q4 2025, for an estimated $746,710,800
- CITADEL ADVISORS LLC added 2,079,416 shares (+244.9%) to their portfolio in Q4 2025, for an estimated $686,436,015
- UBS GROUP AG removed 1,839,868 shares (-40.3%) from their portfolio in Q4 2025, for an estimated $607,358,825
- LONE PINE CAPITAL LLC removed 1,693,347 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $584,712,719
- ROCKEFELLER CAPITAL MANAGEMENT L.P. added 1,568,099 shares (+532.9%) to their portfolio in Q4 2025, for an estimated $517,645,160
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
UnitedHealth Group Government Contracts
We have seen $12,425,826,935 of award payments to $UNH over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- EXPRESS REPORT: R3 FY25 3RD QTR APRIL: $830,362,703
- EXPRESS REPORT: R3 FY25 3RD QTR MAY: $819,320,444
- EXPRESS REPORT: R3 FY25 2ND QTR MARCH: $791,841,212
- EXPRESS REPORT: R3 FY25 2ND QTR FEBRUARY: $730,504,137
- EXPRESS REPORT: R3 FY25 4TH QTR SEP: $725,375,315
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
UnitedHealth Group Analyst Ratings
Wall Street analysts have issued reports on $UNH in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 02/05/2026
- Truist Securities issued a "Buy" rating on 02/02/2026
- Barclays issued a "Overweight" rating on 01/30/2026
- Wells Fargo issued a "Overweight" rating on 01/30/2026
- Leerink Partners issued a "Outperform" rating on 01/28/2026
- Jefferies issued a "Buy" rating on 01/28/2026
- Bernstein issued a "Outperform" rating on 10/30/2025
To track analyst ratings and price targets for UnitedHealth Group, check out Quiver Quantitative's $UNH forecast page.
UnitedHealth Group Price Targets
Multiple analysts have issued price targets for $UNH recently. We have seen 18 analysts offer price targets for $UNH in the last 6 months, with a median target of $387.0.
Here are some recent targets:
- Ann Hynes from Mizuho set a target price of $350.0 on 02/05/2026
- Lisa Gill from JP Morgan set a target price of $389.0 on 02/02/2026
- David Macdonald from Truist Securities set a target price of $370.0 on 02/02/2026
- Stephen Baxter from Wells Fargo set a target price of $370.0 on 01/30/2026
- Andrew Mok from Barclays set a target price of $327.0 on 01/30/2026
- Ben Hendrix from RBC Capital set a target price of $361.0 on 01/28/2026
- An analyst from Leerink Partners set a target price of $345.0 on 01/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
